Biocidal products must be phased off the GB market
The active substance/product type combinations listed below are due to expire under the GB BPR on the following dates:
- Abamectin as a mixture of avermectin B1a (EINECS 265-610-3) and avermectin B1b (EINECS 265-611-9) (CAS 71751-41-2 EC n/a) in product type 18
30 June 2023
- (±)-5-amino-1-(2,6- dichloro-α,α,α,- trifluoro-p-tolyl)-4- trifluoromethylsulfinylpyrazole-3-carbonitrile (1:1) (Fipronil) (CAS 120068-37-3 EC 424-610-5) in product type 18
30 September 2023
- Chlorophacinone (CAS 3691-35-8 EC 223-003-0) in product type 14
30 June 2024
- (RS)-4-hydroxy-3-(3-oxo-1-phenylbutyl)coumarin (Warfarin) (CAS 81-81-2 EC 201-377-6) in product type 14
30 June 2024
- Polyhexamethylene biguanide hydrochloride with a mean number-average molecular weight (Mn) of 1600 and a mean polydispersity (PDI) of 1.8 (PHMB (1600;1.8)) (CAS 27083-27-8 / 32289-58-0 EC n/a) in product types 2, 3 and 11
30 June 2024
Once the approvals expire, the active substances can no longer be used in biocidal products of the relevant product type in GB.
If you hold an affected GB BPR product authorisation or Control of Pesticides Regulations (COPR) product approval, we will contact you about cancelling or revoking your authorisation or approval. You will have an opportunity to submit comments or additional information and we will take account of these when finalising our decision.
If you are aware of any disproportionate negative effects that are likely to arise from the expiry of any of the active substance/product type combinations listed above, please contact us.
|
